These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 16810343

  • 1. Diabetes, insulin, and risk of cancer.
    Schiel R, Beltschikow W, Steiner T, Stein G.
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):169-75. PubMed ID: 16810343
    [Abstract] [Full Text] [Related]

  • 2. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN).
    Schiel R, Müller UA, Braun A, Stein G, Kath R.
    Eur J Med Res; 2005 Aug 17; 10(8):339-44. PubMed ID: 16131475
    [Abstract] [Full Text] [Related]

  • 3. Impaired glucose metabolism in colorectal cancer.
    Ehrmann-Jósko A, Siemińska J, Górnicka B, Ziarkiewicz-Wróblewska B, Ziółkowski B, Muszyński J.
    Scand J Gastroenterol; 2006 Sep 17; 41(9):1079-86. PubMed ID: 16938722
    [Abstract] [Full Text] [Related]

  • 4. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
    Giovannucci E, Michaud D.
    Gastroenterology; 2007 May 17; 132(6):2208-25. PubMed ID: 17498513
    [Abstract] [Full Text] [Related]

  • 5. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU.
    Dtsch Med Wochenschr; 2010 May 17; 135(18):924-9. PubMed ID: 20425680
    [Abstract] [Full Text] [Related]

  • 6. Diabetes mellitus type 2 - an independent risk factor for cancer?
    Grote VA, Becker S, Kaaks R.
    Exp Clin Endocrinol Diabetes; 2010 Jan 17; 118(1):4-8. PubMed ID: 20127570
    [Abstract] [Full Text] [Related]

  • 7. Review article: steatosis, the metabolic syndrome and cancer.
    Bugianesi E.
    Aliment Pharmacol Ther; 2005 Nov 17; 22 Suppl 2():40-3. PubMed ID: 16225471
    [Abstract] [Full Text] [Related]

  • 8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 17; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 9. Type 2 diabetes and cancer: what is the connection?
    Cannata D, Fierz Y, Vijayakumar A, LeRoith D.
    Mt Sinai J Med; 2010 Jun 17; 77(2):197-213. PubMed ID: 20309918
    [Abstract] [Full Text] [Related]

  • 10. Diabetes and the risk of pancreatic cancer.
    Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group.
    N Engl J Med; 1994 Jul 14; 331(2):81-4. PubMed ID: 8208269
    [Abstract] [Full Text] [Related]

  • 11. Pancreatic carcinoma: differences between patients with or without diabetes mellitus.
    Girelli CM, Reguzzoni G, Limido E, Savastano A, Rocca F.
    Recenti Prog Med; 1995 Apr 14; 86(4):143-6. PubMed ID: 7617956
    [Abstract] [Full Text] [Related]

  • 12. Epidemiological aspects of neoplasms in diabetes.
    Nicolucci A.
    Acta Diabetol; 2010 Jun 14; 47(2):87-95. PubMed ID: 20376506
    [Abstract] [Full Text] [Related]

  • 13. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
    Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M.
    Arch Dermatol Res; 2007 Nov 14; 299(9):461-5. PubMed ID: 17726611
    [Abstract] [Full Text] [Related]

  • 14. [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer].
    Kaczka A, Kumor A, Pietruczuk M, Małecka-Panas E.
    Pol Merkur Lekarski; 2007 May 14; 22(131):373-5. PubMed ID: 17679371
    [Abstract] [Full Text] [Related]

  • 15. [Insulin treatment is of value--also in type 2 diabetes].
    Birkeland KI, Vaaler S, Hanssen KF.
    Tidsskr Nor Laegeforen; 1996 Apr 20; 116(10):1233-5. PubMed ID: 8658397
    [Abstract] [Full Text] [Related]

  • 16. Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Herrigel DJ, Moss RA.
    Postgrad Med; 2014 Oct 20; 126(6):106-18. PubMed ID: 25414939
    [Abstract] [Full Text] [Related]

  • 17. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP.
    J Clin Oncol; 2007 Apr 20; 25(12):1476-81. PubMed ID: 17442990
    [Abstract] [Full Text] [Related]

  • 18. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications.
    Velicer CM, Dublin S, White E.
    Prostate Cancer Prostatic Dis; 2007 Apr 20; 10(1):46-51. PubMed ID: 17033617
    [Abstract] [Full Text] [Related]

  • 19. Hyperproinsulinemia segregates young adult patients with newly diagnosed autoimmune (type 1) and non-autoimmune (type 2) diabetes.
    Bolinder J, Fernlund P, Borg H, Arnqvist HJ, Björk E, Blohmé G, Eriksson JW, Nyström L, Ostman J, Sundkvist G.
    Scand J Clin Lab Invest; 2005 Apr 20; 65(7):585-94. PubMed ID: 16271990
    [Abstract] [Full Text] [Related]

  • 20. Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study.
    Halimi JM, Bonnet F, Lange C, Balkau B, Tichet J, Marre M, DESIR Study Group.
    J Hypertens; 2008 Nov 20; 26(11):2198-206. PubMed ID: 18854761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.